Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer’s Treatments with Different Duration and Route of Administration ; day:7 ; month:5 ; year:2024 ; pages:1-6
The journal of prevention of Alzheimer's disease ; (7.5.2024), 1-6
- Urheber
-
Ozawa, T.
Franguridi, G.
Mattke, Soeren
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2024.81
- URN
-
urn:nbn:de:101:1-2407151352499.081219411433
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ozawa, T.
- Franguridi, G.
- Mattke, Soeren
- SpringerLink (Online service)
Ähnliche Objekte (12)
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Good problems to have? Policy and societal implications of a disease-modifying therapy for presymptomatic late-onset Alzheimer’s disease
Disease-modifying treatments in Alzheimer’s disease
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Con: are we ready to translate Alzheimer’s disease-modifying therapies to people with down syndrome?
Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer’s Disease-Modifying Therapy
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review